Efficient precise in vivo base editing in adult dystrophic mice
Preprint
Abstract
Background: Recent advances in the base editing technology have created an exciting opportunity to precisely correct disease-causing mutations. However, the large size of base editors and their inherited off-target activities pose challenges for in vivo base editing. Moreover, the requirement of a protospacer adjacent motif (PAM) sequence within a suitable window near the mutation site further limits the targeting feasibility. In this work, we rationally improved the adenine base editor (ABE) to overcome these challenges and demonstrated the exceptionally high efficiency to precisely edit the Duchenne muscular dystrophy (DMD) mutation in adult mice. Methods: We employed a fluorescence reporter assay to assess the feasibility of ABE to correct the dystrophin mutation in mdx 4cv mice. The intein protein trans-splicing (PTS) was used to split the oversized ABE into two halves for efficient packaging into adeno-associated virus 9 (AAV9). The ABE with broadened PAM recognition (ABE-NG) was rationally re-designed for improved off-target RNA editing activity and on-target DNA editing efficiency. The mdx 4cv mice at the 5 weeks of age receiving intramuscular or intravenous injections of AAV9 carrying the improved ABE-NG were analyzed at 10 weeks or 10 months of age. The editing outcomes were analyzed by Sanger and deep sequencing of the amplicons, immunofluorescence staining, Western blot and contractile function measurements. The off-target activities, host immune response and long-term toxicity were analyzed by deep sequencing, ELISA and serological assays, respectively. Results: We showed efficient in vitro base correction of the dystrophin mutation carried in mdx 4cv mice using ABE-NG. The super-fast intein-splits of ABE-NG enabled the expression of full-length ABE-NG and efficient AAV9 packaging. We rationally improved ABE-NG with eliminated off-target RNA editing activity and minimal PAM requirement, and packaged into AAV9 (AAV9-iNG). Intramuscular and intravenous administration of AAV9-iNG resulted in dystrophin restoration and functional improvement. At 10 months after AAV9-iNG treatment, a near complete rescue of dystrophin was measured in mdx 4cv mouse hearts. The off-target activities remained low and no obvious toxicity was detected. Conclusions: This study highlights the promise of permanent base editing using iABE-NG for the treatment of monogenic diseases, in particular, the genetic cardiomyopathies.Keywords
All Related Versions
- Published version: Nature Communications, 12 (1), 1.
This publication has 65 references indexed in Scilit:
- In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic MiceCirculation Research, 2017
- Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophyNature Communications, 2017
- A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle CellsCell Stem Cell, 2016
- In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophyScience, 2016
- Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophyScience, 2016
- In vivo gene editing in dystrophic mouse muscle and muscle stem cellsScience, 2016
- Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophyNature Communications, 2015
- Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9Stem Cell Reports, 2015
- Evidence‐based path to newborn screening for duchenne muscular dystrophyAnnals of Neurology, 2012
- Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individualsCell, 1987